{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260420766130/en/FDA-Grants-Priority-Review-for-KEYTRUDA%C2%AE-pembrolizumab-and-KEYTRUDA-QLEX%E2%84%A2-pembrolizumab-and-berahyaluronidase-alfa-pmph-Each-with-Padcev%C2%AE-enfortumab-vedotin-ejfv-for-Cisplatin-Eligible-Patients-with-Muscle-Invasive-Bladder-Cancer", "message": "News view counter 670962 successfully enlarged"}